Search results for: Adrian Towse
Filter search results
Previews of Forthcoming Publications
27 July 2011
…of approaches can be identified. Towse, A., Keuffel, E., Kettler, H.E. and Ridley, D.B. (2011) Drugs and vaccines for developing countries. Occasional Paper. London: Office of Health Economics. In ‘Measuring…
Incentives for R&D for New Antimicrobial Drugs
31 August 2011
…this blog post. Sharma and Towse Just published by OHE researchers is a comprehensive analysis* of what policy measures are needed to counter the growing global problem of antimicrobial resistance….
As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?
26 September 2018
…on the CGD website and can be accessed here. Ferraro, J., Towse, A., and Mestre-Ferrandiz, J. 2017. Incentives for New Drugs to Tackle Anti-Microbial Resistance. OHE briefing. RePEc Berdud, M.,…
Making the Most of Health Data to Deliver Pharmaceutical Innovation: What Are the Legal Barriers?
20 December 2018
…and underpins our legal frameworks. Cole, A. and Towse, A., 2018. Legal Barriers to Better the Better Use of Health Data to Deliver Pharmaceutical Innovation. OHE Consulting Report, London: Office…
Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs
21 February 2019
…Sussex, J. and Lorgelly, P., 2019. Making Outcome-Based Payment a Reality in the NHS. OHE, RAND Europe, KCL and Cancer Research UK Research Paper. Available at: https://www.ohe.org/publications/making-outcome-based-payment-reality-nhs Cole, A., Towse,…
Quality of Life and Rare Disease: Lessons from Spinal Muscular Atrophy
2 April 2019
…Muscular Atrophy. OHE Briefing, London: Office of Health Economics. RePEc. Towse, A. and Garau, M., 2018. Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence. OHE Consulting Report….
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
…Cole, A., Towse, A., Lorgelly, P., and Sullivan, R., 2018. Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. OHE Research Paper 18/04. RePEc. Lorgelly, P.K. and Neri,…
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
…at: https://www.ohe.org/publications/meningococcal-vaccines-international-comparison-decisionmaking-processes-frameworks Berdud, M., Towse, A., Jofre-Bonet, M., 2020. The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to…
Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison
1 June 2000
…in the UK, the US and Germany (Reekie, 1996; Towse and Leighton, 1999). However, both theory and casual empirical evidence suggest that strict price regulation may undermine competition. Generic market…